Jeff Reese
Last active: 1/7/2021

Genetics of the patent ductus arteriosus (PDA) and pharmacogenetics of PDA treatment.

Lewis TR, Shelton EL, Van Driest SL, Kannankeril PJ, Reese J
Semin Fetal Neonatal Med. 2018 23 (4): 232-238

PMID: 29510900 · PMCID: PMC6098727 · DOI:10.1016/j.siny.2018.02.006

Patent ductus arteriosus (PDA) is a frequent, complex, and difficult to treat clinical syndrome among preterm infants in the neonatal intensive care unit. In addition to known clinical risk factors, there are emerging data about genetic predisposition to PDA in both animal and human models. Clinical response and toxicity from drugs used to treat PDA are highly variable. Developmental and genetic aspects of pharmacokinetics and pharmacodynamics influence exposure and response to pharmacologic therapies. Given the variable efficacy and toxicity of known drug therapies, novel therapeutic targets for PDA treatment offer the promise of precision medicine. This review addresses the known genetic contributions to prolonged ductal patency, variability in response to drug therapy for PDA, and potential novel drug targets for future PDA treatment discovery.

Copyright © 2018 Elsevier Ltd. All rights reserved.

MeSH Terms (11)

Acetaminophen Animals Disease Models, Animal Ductus Arteriosus, Patent Genetic Predisposition to Disease Humans Ibuprofen Indomethacin Infant, Newborn Infant, Premature Pharmacogenetics

Connections (1)

This publication is referenced by other Labnodes entities: